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SUMMARY
Therapies that target estrogen signaling have transformed the treatment of breast cancer. However, the
effectiveness of these agents is limited by the development of resistance. Here, an RNAi screen was used
to identify modifiers of tamoxifen sensitivity. We demonstrate that CDK10 is an important determinant of
resistance to endocrine therapies and show that CDK10 silencing increases ETS2-driven transcription of
c-RAF, resulting inMAPKpathway activation and loss of tumor cell reliance upon estrogen signaling. Patients
with ERa-positive tumors that express low levels of CDK10 relapse early on tamoxifen, demonstrating the
clinical significance of these observations. The association of low levels of CDK10 with methylation of the
CDK10 promoter suggests a mechanism by which CDK10 expression is reduced in tumors.INTRODUCTION
Approximately 70% of breast tumors express estrogen receptor
a (ERa), and of these, the majority are dependent on estrogen
signaling (EBCTCG, 1998). ERa acts as a hormone-dependent
nuclear transcription factor; binding of estrogen to ERa causes
a conformational change within the receptor that allows dimer-
ization and binding to estrogen-responsive elements (EREs)
located in the promoter region of ERa target genes. This ER/
ERE interaction leads to the recruitment of cofactors that facili-
tate gene transcription (Mangelsdorf et al., 1995). Since most
ERa-positive breast cancers are fully dependent on estrogen
signaling, they can be effectively treated with antiestrogens
such as tamoxifen or aromatase inhibitors that prevent estrogen
synthesis (EBCTCG, 1998). Tamoxifen binds to ERa, blocking
the interaction between estrogen and its receptor. This inhibition
of ERa leads to cell cycle arrest at the G1 cell cycle checkpoint,
limiting cellular proliferation (Musgrove and Sutherland, 1994;
Cariou et al., 2000). Despite its widespread use, the effective-ness of tamoxifen is limited by the development of drug resis-
tance; all patients with metastatic disease and 40% of early-
stage breast cancer patients treated with adjuvant tamoxifen
eventually relapse with tamoxifen-resistant disease (Jordan,
1995). Aromatase inhibitors, which block the synthesis of estro-
gen, have recently been shown to have superior efficacy and
improved tolerability for the treatment of postmenopausal,
ERa-positive breast cancer patients compared to tamoxifen
(Baum et al., 2003). Initially it was envisaged that resistance to
these agents would be less frequent than for tamoxifen, but up
to 50% of treated patients develop resistance to aromatase
inhibitors (Anderson et al., 2007).
Two major mechanisms have been proposed by which resis-
tance to endocrine therapy may occur. First, continued ERa sig-
naling in the presence of an ERa antagonist or the absence of
estrogen may occur, known as ligand-independent ERa activa-
tion (Shou et al., 2004). Second, the reliance of tumors upon
ERa signaling may be circumvented by the activation of
non-ERa growth-promoting pathways (El-Ashry et al., 1997;SIGNIFICANCE
Understanding the molecular basis of the response to tamoxifen and other antiendocrine agents is of importance in delin-
eatingmechanisms of resistance to these clinically important therapies.Wedemonstrate that high-throughput loss-of-func-
tion screens have the ability to identify determinants of response to endocrine therapies that have clear clinical significance.
The identification of CDK10 as a critical determinant of tamoxifen response and themolecular mechanisms bywhich CDK10
dysfunction modulates the response to tamoxifen may allow alternative therapeutic approaches. Our findings indicate that
loss of CDK10 expression may be a major determinant of tamoxifen resistance.
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CDK10 Mediates Endocrine Therapy ResistanceOh et al., 2001). The activity of signal-transducing kinases has
been implicated in both of these mechanisms (Gee et al., 2001;
Pe´rez-Tenorio et al., 2002). While the study of individual kinases
has been informative, a complementary approach is to analyze
all protein kinases simultaneously to uncover alternative mecha-
nisms of resistance. Approaches such as high-throughput RNA
interference (RNAi) screening now allow such systematic analy-
sis to be performed (Iorns et al., 2007).
The development of RNAi libraries, which are composed of
reagents that allow the selective silencing of specific transcripts,
has made it possible to conduct high-throughput screens (HTSs)
that interrogate phenotypes associated with the loss of function
of many genes (Iorns et al., 2007). Furthermore, siRNA libraries
have been used to identify key determinants of resistance to
chemotherapeutic drugs such as paclitaxel (Whitehurst et al.,
2007; Swanton et al., 2007). We used a library of synthetic siRNA
oligonucleotide pools targeting the expression of all kinases in
the human genome to identify those that, when silenced, cause
tamoxifen resistance in vitro. We demonstrate that targeting
CDK10 causes resistance to tamoxifen and other endocrine
therapies in vitro and that low expression of CDK10 is associated
with a poor clinical response to tamoxifen.
RESULTS
Tamoxifen Resistance High-Throughput siRNA Screen
To identify nonredundant determinants of tamoxifen resistance,
we designed a robust, high-throughput RNA interference screen
targeting 779 known and putative kinases (Figure 1A). The screen
involved transfecting an ERa-positive, tamoxifen-sensitive
breast cancer cell line (MCF7) with a 96-well plate arrayed library
of siRNA duplexes. Twenty-four hours after transfection, cells
were divided into replica plates, and half were treated with 4OH
tamoxifen (the active tamoxifen metabolite) and half with vehicle
(Figure 1A). Seven days later, cell viability in each plate was
measured to assess the effect of each siRNA on cell growth (as
assessed in the vehicle-treated plates) and also the effect of ex-
posure to 4OH tamoxifen. A medium-term time course of drug
treatment was chosen as opposed to short-term treatments
(1–2 days) commonly used in chemoresistance screens to in-
crease the sensitivity of the screen. We used a library of siRNA ar-
rayed as SMARTpools; each SMARTpool (contained within one
well of a 96-well plate) was composed of four distinct siRNA spe-
cies targeting different sequences of the same target transcript.
We validated the performance of MCF7 cells in the high-
throughput format as follows: (1) transfection of MCF7 cells
with siRNA targeting genes essential for cellular viability (such
as PLK1) was observed to cause a reduction in viability of
more than 90%, compared to transfection with a nontargeting
siRNA, siControl, indicating that high-efficiency transfection
could be achieved; and (2) transfection of MCF7 with siControl
did not reduce cellular viability more than 20%, compared to
mock-transfected cells, indicating that these cells could be
transfected without excessive nonspecific toxicity, which would
reduce the sensitivity of the screen. The cell numbers plated for
transfection and at the division of cells into replica plates after
transfection and before 4OH tamoxifen/vehicle treatment were
also titrated. This ensured efficient transfection and prevented
cells reaching confluence after vehicle treatment, as this would
92 Cancer Cell 13, 91–104, February 2008 ª2008 Elsevier Inc.have the potential to mask 4OH tamoxifen sensitivity. We used
the Celltiter Glo (Promega) method of cell viability measurement,
as opposed to other methods (MTT, MTS assay), as this reagent
generated the most reproducible and sensitive measurements of
difference in viability. Following optimization, the screen was
repeated twice with internal duplication, and comparison of
data from each screen revealed high reproducibility (Figure 1B)
with the results approximating a normal distribution (Figure S1).
Data from both screens were combined in the final analysis
(Figure 1C). The 20 siRNAs causing the most significant resis-
tance to 4OH tamoxifen are listed in Table S1.
Validation and Exclusion of Off-Target Effects
In addition to silencing specific transcripts, off-target effects of
siRNAs can also occur (Iorns et al., 2007). To validate the
specificity of the effects observed, the most potent tamoxifen
resistance causing hits were reassayed using each of the four
different siRNA species that comprise the SMARTpools. It is
generally considered that observation of a phenotype caused
by two distinct siRNA species indicates that it is unlikely to be
the result of an off-target effect (Echeverri et al., 2006).
Of the four most potent resistance causing hits, three were
judged likely to be on-target: Cyclin-Dependent Kinase 10
(CDK10, Entrez GeneID 8558), CDC2-related protein kinase 7
(CRK7, Entrez GeneID 51755), and Mitogen-Activated Protein
Kinase Kinase 7 (MAP2K7, Entrez GeneID 5609) (Figure 1D).
TTK1 was not re-examined because of the excessive toxicity
associated with silencing of this gene in the absence of 4OH
tamoxifen. We further investigated the mechanism of resistance
to tamoxifen induced by CDK10 silencing.
CDK10 Silencing Causes Resistance to Tamoxifen
and Estrogen Deprivation
CDK10 gene silencing by siRNA was confirmed by quantitative
PCR and western blotting (Figures 2A and 2B and Figure S2A).
The two CDK10-targeting siRNAs that caused the most signifi-
cant effects on tamoxifen sensitivity were also shown to cause
the most significant CDK10 silencing (Figure 2C). To confirm
the validity of the results from the HTS, dose-response curves
were performed (Figure 2D). CDK10 silencing significantly de-
creased sensitivity to tamoxifen (siControl SF60 = 28 nM, CDK10
SMARTpool SF60 = 488 nM; a 17-fold reduction in sensitivity).
Further confirmation that CDK10 silencing causes tamoxifen
resistance was provided by replicating the dose-response effect
with an ONTARGETplus SMARTpool (Dharmacon) targeting
CDK10, which also significantly decreased tamoxifen sensitivity
(Figure 2E and Figure S2B). The siRNAs that comprise
ONTARGETplus SMARTpools have been chemically modified
to minimize off-target effects (Jackson et al., 2006). We also in-
vestigated whether the CDK10 effect on tamoxifen sensitivity
could be trivially explained by an increase in cellular proliferation
or by resistance to apoptosis. In fact, CDK10 silencing resulted in
a small decrease in cell viability and did not cause resistance to
apoptosis (Figures S3 and S4).
To confirm whether the CDK10 silencing effect was specific to
tamoxifen or common to other forms of ERa antagonism, we
analyzed the effect of CDK10 siRNA on sensitivity to estrogen
deprivation, a model for aromatase inhibition (Santen et al.,
2005). CDK10 silencing significantly decreased sensitivity to
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CDK10 Mediates Endocrine Therapy ResistanceFigure 1. A Tamoxifen Resistance Screen with a Protein Kinase siRNA Library
(A) High-throughput screen (HTS) method. MCF7 cells plated in 96-well plates were transfected with siRNA. Each transfection plate contained 80 experimental
siRNAs (SMARTpools of four different siRNA targeting the same gene), indicated in black, supplemented with ten wells of nontargeting siControl, indicated in red.
Transfected cells were divided into four replica plates, half treated with ethanol vehicle alone and half with 4OH tamoxifen at 50 nM, the SF80 of MCF7. Cell viability
was assessed after 7 days of 4OH tamoxifen exposure using CellTiter-Glo Luminescent Cell Viability Assay (Promega).
(B) Reproducibility of HTS method. Correlation of the effect of siRNA on cell growth in vehicle-treated plates from two replicates of the entire screen. Spearman
correlation coefficient, r2 = 0.71.
(C) Scatter plot of averaged Z scores from tamoxifen resistance screen carried out in duplicate. Black diamonds, siRNA SMARTpools targeting 779 protein kinase
genes, Red diamonds, siControl.
(D) Validation of resistance hits from the tamoxifen HTS. Tamoxifen sensitivity assay repeated in triplicate with the four different siRNAs originally in each
SMARTpool and the SMARTpool, all targeting the same kinase. Surviving fractions following tamoxifen treatment are shown, including those after transfection
with siControl (Red). CRK7 and MAP2K7 revalidate with all four siRNAs; CDK10 revalidates with three siRNAs. *p < 0.05 compared to siControl (Student’s t test).
Error bars represent the standard error of the mean (SEM).Cancer Cell 13, 91–104, February 2008 ª2008 Elsevier Inc. 93
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CDK10 Mediates Endocrine Therapy ResistanceFigure 2. CDK10 Silencing Decreases
Sensitivity to Tamoxifen and Estrogen
Deprivation
(A) CDK10 mRNA levels quantified by qPCR
following transfection of siRNA into MCF7 cells.
CDK10 expression is shown relative to expression
in siControl-transfected cells. Individual siRNAs
1 and 4 and the CDK10 SMARTpool caused
the most significant reduction in CDK10 mRNA
expression. *p < 0.01 compared to siControl-
transfected cells (Student’s t test). Error bars rep-
resent the SEM.
(B) Western blot analysis of lysates prepared from
MCF7 cells transfected with pReceiver CDK10 HA
and siRNA. Antibodies recognizing CDK10 were
used with b-tubulin as a loading control. Individual
siRNAs 1, 3, and 4 and the CDK10 SMARTpool
significantly reduced CDK10 protein expression
compared to siControl-transfected cells.
(C) Surviving fractions following 4OH tamoxifen
treatment with the four individual siRNAs and the
SMARTpool targeting CDK10, and siControl.
Individual siRNAs 1 and 4 and the CDK10 SMART-
pool most significantly reduced tamoxifen sensi-
tivity. *p < 0.01 compared to siControl-transfected
cells (Student’s t test). Error bars represent the
SEM.
(D) Cell viability assay in MCF7 cells transfected
with CDK10 SMARTpool, individual CDK10 siRNAs
1 and 4, or siControl and treated with 4OH tamox-
ifen. CDK10-silenced cells have significantly de-
creased sensitivity to 4OH tamoxifen. Error bars
represent the SEM.
(E) Cell viability assay in MCF7 cells transfected
with CDK10 ONTARGETplus SMARTpool, or
ONTARGETplus siControl and treated with 4OH
tamoxifen. CDK10-silenced cells have signifi-
cantly decreased sensitivity to 4OH tamoxifen.
Error bars represent the SEM.
(F) Cell viability assay in MCF7 cells transfected
with CDK10 SMARTpool, individual CDK10
siRNAs 1 and 4, or siControl and deprived of
estradiol. CDK10 silenced cells have significantly
decreased sensitivity to estrogen deprivation.
*p < 0.05 compared to siControl (Student’s
t test). Error bars represent the SEM.estrogen deprivation (Figure 2F), indicating that suppression of
CDK10 causes resistance to inhibition of ERa signaling gener-
ally, rather than tamoxifen specifically.
A Reduction in CDK10 Expression Circumvents G1 Cell
Cycle Arrest in Cells Deprived of Estrogen Signaling
The antiproliferative effect of antiestrogens results in the induc-
tion of cell cycle arrest at the G1 checkpoint, as characterized
by an increase in cells in the G1 phase of the cycle and a conse-
quential decrease in the S phase proportion (Wilcken et al.,
1997). We explored the possibility that a reduction in CDK10
expression circumvents this tamoxifen-induced cell cycle arrest.
siControl-transfected cells treated with tamoxifen exhibited the
expected increase in G1 and decrease in S phase populations
(Figures 3A and 3B and Table S2). In contrast, tamoxifen-treated,
CDK10-silenced cells showed significantly reduced G1 increase,
and a significantly smaller decrease in the number of S phase
94 Cancer Cell 13, 91–104, February 2008 ª2008 Elsevier Inc.cells (Figures 3A and 3B and Table S2), indicative of a decreased
tamoxifen-induced G1 arrest.
CYCLIN D1 expression actively drives transit through the G1
checkpoint. CYCLIN D1 binds to and activates CDK4/6, which
phosphorylate and inactivate the Retinoblastoma 1 protein
(RB1), allowing progression through the restriction point within
G1 (Sherr, 1996). Overexpression of CYCLIN D1 has also been
shown to cause entry into S phase of cells previously arrested
at the G1 checkpoint, reversing the growth inhibitory effects of an-
tiestrogens (Wilcken et al., 1997). Both mRNA and protein levels
of CYCLIN D1 were significantly elevated in CDK10-silenced
cells (Figures 3C and 3D), and in addition, the levels of phosphor-
ylated RB1 were also significantly elevated (Figure 3E). These
results were consistent with the hypothesis that G1 cell cycle
arrest in tamoxifen-treated cells is circumvented by a reduction
in CDK10 expression, resulting in decreased sensitivity to tamox-
ifen. This effect appears to be mediated by an increase in CYCLIN
D1 expression and subsequent phosphorylation of RB1.
Cancer Cell
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Tamoxifen-Induced G1 Arrest
(A) Resistance to tamoxifen in CDK10-silenced
cells is characterized by decreased tamoxifen-
induced G1 arrest. Cells were transfected with ei-
ther CDK10 SMARTpool or siControl. Cell cycle
profiles were assessed by propidium iodide (PI)
staining and fluorescence-activated cell scanning
(FACS) from cell aliquots taken both before and
after treatment with 4OH tamoxifen.
(B) Absolute differences were calculated by sub-
tracting the percentage of cells in each phase of
the cell cycle before 4OH tamoxifen treatment
from the percentage of cells in each phase after
4OH tamoxifen treatment. Significantly smaller dif-
ferences in G1 and S phases after 4OH tamoxifen
treatment were observed in CDK10-silenced cells,
indicating decreased tamoxifen-induced G1 ar-
rest. *p < 0.05 compared to siControl (Student’s t
test). Error bars represent the SEM.
(C) CDK10 SMARTpool-transfected cells have sig-
nificantly higher CCND1 expression than siCon-
trol-transfected cells. qPCR on cDNA prepared
from MCF7 cells transfected with siRNA for 48 hr
followed by treatment with 1 nM estradiol, or left
untreated for 24 hr. For CDK10 SMARTpool-
transfected cells, p < 0.05 compared to matched
siControl-transfected cells (Student’s t test). Error
bars represent the SEM.
(D) CDK10 SMARTpool-transfected cells have sig-
nificantly higher expression of CYCLIN D1 protein
than siControl-transfected cells. MCF7 cells trans-
fected 48 hr earlier with siRNA were treated with
1 nM estradiol or 1 nM estradiol plus 100 nM
4OH tamoxifen, or left untreated. Lysates were
made 24 hr following treatment. Antibodies recog-
nizing CYCLIN D1 were used with b-tubulin as
a loading control.
(E) CDK10 SMARTpool-transfected cells have
significantly higher levels of phosphorylated RB1
than siControl-transfected cells. MCF7 cells trans-
fected 48 hr earlier with siRNA were treated with
1 nM estradiol or 1 nM estradiol plus 100 nM
4OH tamoxifen, or left untreated. Lysates were
made 24 hr following treatment. Antibodies recog-
nizing phospho RB1 and total RB1 were used with
Ezrin as a loading control.Tamoxifen Resistance Is Not Caused by Ligand-
Independent ERa Activation in CDK10-Silenced Cells
ERa stimulation causes cellular proliferation by increasing
CYCLIN D1 (CCND1) transcription (Altucci et al., 1996). A pos-
sible mechanism of tamoxifen resistance is ligand-independent
ERa-induced transcription, resulting in continued ERa signaling
in the presence of tamoxifen (Shou et al., 2004). We explored
the possibility that the increase in CCND1 observed in
CDK10-silenced cells was due to ligand-independent ERa acti-
vation as indicated by ERa phosphorylation. There were no sig-
nificant changes in either the expression or activation of ERa
(Figure 4A). If ligand-independent activation of ERa was occur-
ring, increases in the expression of other ERa regulated genes
would also be expected. We showed that levels of the ERa
target gene, the progesterone receptor (PR), were unaffected
following CDK10 silencing (Figure 4B). We also assessed the
expression of TFF1 (pS2), the product of one of the best-characterized ERa-regulated genes. Transcription of TFF1 is
tightly controlled by the binding of ERa to an ERE within the
TFF1 promoter (Jakowlew et al., 1984). There was no increase
in TFF1 expression after CDK10 silencing, rather a reduction in
TFF1 expression was observed (Figure 4C). These results sug-
gested that ligand-independent activation of ERa signaling was
unlikely to be the cause of tamoxifen resistance in CDK10-
silenced cells. To further confirm that ERa was unlikely to be
involved in resistance to tamoxifen in CDK10-silenced cells,
we examined the effect of CDK10 silencing on sensitivity to
ICI 182780, an agent that induces ERa degradation (Jones,
2002). CDK10 silencing significantly decreased sensitivity
to ICI 182780 (siControl SF60 = 4 nM, CDK10 SMARTpool
SF60 = 32 nM; an 8-fold reduction in sensitivity) (Figure 4D), fur-
ther supporting the hypothesis that CDK10 silencing does not
cause tamoxifen resistance by promoting ligand-independent
ERa signaling.Cancer Cell 13, 91–104, February 2008 ª2008 Elsevier Inc. 95
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(A) CDK10 SMARTpool-transfected cells do not have altered activation or expression of ERa compared with siControl-transfected cells. Left panel: MCF7 cells
transfected 48 hr earlier with siRNA were treated with 1 nM estradiol or 1 nM estradiol plus 100 nM 4OH tamoxifen, or left untreated. Lysates were made 24 hr
following treatment. Antibodies recognizing phosphoserine 118 and total ERawere used with b-tubulin as a loading control. Right panel: qPCR on cDNA prepared
from MCF7 cells transfected with siRNA for 48 hr followed by treatment with 1 nM estradiol or 1 nM estradiol plus 100 nM 4OH tamoxifen, or left untreated for
24 hr. Error bars represent the SEM.
(B) CDK10 SMARTpool-transfected cells do not have increased expression of the ERa-regulated gene PR compared with siControl-transfected cells. Left panel:
MCF7 cells transfected 48 hr earlier with siRNA were treated with 1 nM estradiol or 1 nM estradiol plus 100 nM 4OH tamoxifen, or left untreated. Lysates were
made 24 hr following treatment. An antibody recognizing PR was used with b-tubulin as a loading control. Right panel: qPCR on cDNA prepared from MCF7 cells
transfected with siRNA for 48 hr followed by treatment with 1 nM estradiol or 1 nM estradiol plus 100 nM 4OH tamoxifen, or left untreated for 24 hr. Error bars
represent the SEM.
(C) CDK10 SMARTpool-transfected cells have significantly lower expression of ERa-regulated gene TFF1 compared with siControl-transfected cells. Left panel:
MCF7 cells transfected 48 hr earlier with siRNA were treated with 1 nM estradiol or 1 nM estradiol plus 100 nM 4OH tamoxifen, or left untreated. Lysates were
96 Cancer Cell 13, 91–104, February 2008 ª2008 Elsevier Inc.
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MAPK Pathway
The reduction observed in expression of TFF1 (Figure 4C)
supported the hypothesis that tamoxifen resistance occurs
through activation of growth factor signaling pathways that cir-
cumvent tumor reliance on ERa signaling. Previous studies
have shown that transfection of constitutively active MEK1 or
c-RAF into MCF7 cells, which results in hyperactivation of p42/
p44 MAPK, caused loss of ERa-mediated gene expression,
characterized by TFF1 suppression and acquisition of antiestro-
gen resistance (El-Ashry et al., 1997; Oh et al., 2001). In addition,
activation of p42/p44 MAPK has been shown to cause an in-
crease in CYCLIN D1 expression (Lavoie et al., 1996). Therefore,
we examined whether the p42/p44 MAPK pathway was
activated in CDK10-silenced cells as measured by the phos-
phorylation of p42/p44 MAPK and MEK1,2. This indicated that
phosphorylation of these MAPK pathway components was
enhanced following CDK10 silencing (Figures 5A and 5B). To de-
termine whether this activation was the cause of tamoxifen resis-
tance in cells with reduced CDK10 expression, p42/p44 MAPK
and MEK1,2 were silenced by siRNA in conjunction with sup-
pression of CDK10 expression. Sensitivity to tamoxifen in this
situation was restored (Figures 5C and 5D), suggesting that a re-
duction of CDK10 expression causes tamoxifen resistance by
activation of the p42/p44 MAPK signaling pathway, circumvent-
ing the reliance upon ERa signaling.
CDK10 Silencing Increases c-RAF Expression
To determine the mechanism by which CDK10 silencing mod-
ifies p42/p44 MAPK signaling, the activation of the upstream
pathway components c-RAF and Ras was examined. Phosphor-
ylation of c-RAF was significantly increased in CDK10-silenced
cells, and levels of total c-RAF protein were also increased
(Figure 6A). c-RAFmRNA levels were also significantly increased
in CDK10-silenced cells (Figure 6B). To determine whether this
increase in expression was the cause of tamoxifen resistance
in cells with reduced CDK10 expression, c-RAF expression
was silenced by siRNA in conjunction with suppression of
CDK10 expression. Sensitivity to tamoxifen in this situation
was partially restored (Figure 6C and Figure S2C), suggesting
that the effects of CDK10 silencing were c-RAF dependent.
Ras was not activated by CDK10 silencing (Figure 6D). There-
fore, activation of the MAPK pathway seemed likely to be medi-
ated by c-RAF levels, caused by the increased transcription of
c-RAF. To confirm that overexpression of c-RAF was sufficient
to increase the levels of activated c-RAF and to activate down-
stream components of the MAPK pathway, wild-type c-RAF
was overexpressed in MCF7 cells. Overexpression of wild-type
c-RAF also resulted in increased levels of phosphorylated
c-RAF (Figure 6E) and caused increased levels of phosphory-
lated p42/p44 MAPK (Figure 6F) suggesting that the increased
MAPK activity that characterizes tamoxifen resistance in
CDK10-silenced cells was driven by elevated c-RAF expression.Increased c-RAF Transcription Is Mediated by ETS2
The ETS2 transcription factor has previously been shown to
interact with CDK10. ETS2 transactivation is repressed by
CDK10 binding (Kasten and Giordano, 2001), therefore it is pos-
sible that aberrant ETS2 activity could drive the increased
expression of c-RAF in CDK10-silenced cells. To determine
whether the increase in c-RAF transcription observed in CDK10-
silenced cells was dependent on ETS2, ETS2 was silenced in
combination with CDK10, and the levels of c-RAF mRNA were
measured using quantitative PCR. c-RAF mRNA levels were de-
creased when ETS2 was silenced in combination with CDK10
(Figure 7A). c-RAF protein levels were also decreased when
ETS2 was silenced in combination with CDK10, as were the
levels of phosphorylated p42/p44 MAPK (Figure 7B). To deter-
mine whether the decrease in tamoxifen sensitivity observed in
cells with reduced CDK10 expression was dependent on
ETS2, ETS2 expression was silenced by siRNA in conjunction
with suppression of CDK10 expression. Sensitivity to tamoxifen
in this context was partially restored (Figure 7C and Figure S2D),
suggesting that a reduction of CDK10 expression caused tamox-
ifen resistance by relieving the inhibition of ETS2 transactivation
of c-RAF. We confirmed that CDK10 binds to ETS2 using coim-
munoprecipitation (Co-IP) (Figure 7D and Figure S5) and identi-
fied a putative ETS2-binding site in the c-RAF promoter (Fig-
ure 7E). We demonstrated using chromatin IP (ChIP) that ETS2
and CDK10 bind to this site (Figure 7F) and showed that silencing
of CDK10 results in increased binding of ETS2 to the ETS2 bind-
ing site in the c-RAF promoter (Figure 7G). These results suggest
that CDK10 silencing relieves repression of ETS2 transactivation
of the c-RAF promoter, resulting in increased recruitment of
ETS2 to the c-RAF promoter and increased expression of c-RAF.
Low CDK10 Expression Is Associated with Clinical
Resistance to Tamoxifen
To assess the clinical significance of our observations, CDK10
expression levels were analyzed in 87 ERa-positive breast
tumors from patients treated with adjuvant tamoxifen (Loi
et al., 2007). Low CDK10 expression was associated with a sta-
tistically significantly shorter time to distant relapse of disease
(p = 0.0205, Figure 8A), and there was a trend to shorter overall
survival (p = 0.0793, Figure 8B), suggesting that reduced CDK10
expression is associated with clinical resistance to tamoxifen in
patients, consistent with our in vitro studies. LowCDK10 expres-
sion was not associated with well-established prognostic fac-
tors, including age, tumor size, grade, or node positivity (Table
S3). To confirm these findings, CDK10 expression was mea-
sured using quantitative PCR in a second independent set of
ERa-positive breast tumors from patients treated with adjuvant
tamoxifen. Consistent with the data presented above, low
CDK10 expression was strongly associated with a statistically
significantly shorter time to disease progression (p < 0.0001,
Figure 8C) and significantly shorter overall survival (p < 0.0001,
Figure 8D), further suggesting that reduced CDK10 expressionmade 24 hr following treatment. An antibody recognizing TFF1 was used with b-tubulin as a loading control. Right panel: qPCR on cDNA prepared from MCF7
cells transfected with siRNA for 48 hr followed by treatment with 1 nM estradiol or 1 nM estradiol plus 100 nM 4OH tamoxifen, or left untreated for 24 hr. For
CDK10 SMARTpool-transfected cells treated with E2, p < 0.05 compared to matched siControl-transfected cells (Student’s t test). Error bars represent the SEM.
(D) CDK10 silencing decreases sensitivity to ICI 182780. Cell viability assay in MCF7 cells transfected with CDK10 SMARTpool, individual CDK10 siRNAs 1 and 4,
or siControl and treated with ICI 182780. CDK10-silenced cells have significantly decreased sensitivity to ICI 182780. Error bars represent the SEM.
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(A) Increased levels of phosphorylated p42/p44 MAPK in CDK10 silenced cells. MCF7 cells transfected 48 hr earlier with siRNA were treated with 1 nM estradiol or
1 nM estradiol plus 100 nM 4OH tamoxifen, or left untreated. Lysates were made 24 hr following treatment. Antibodies recognizing phospho and total p42/p44
MAPK were used with b-tubulin as a loading control.
(B) Increased levels of phosphorylated MEK1,2 in CDK10-silenced cells. MCF7 cells transfected 48 hr earlier with siRNA were treated with 1 nM estradiol or 1 nM
estradiol plus 100 nM 4OH tamoxifen, or left untreated. Lysates were made 24 hr following treatment. Antibodies recognizing phospho and total MEK1,2 were
used with b-tubulin as a loading control.
(C) Silencing of p42/p44 MAPK restores 4OH tamoxifen sensitivity to CDK10-silenced cells. Left panel: Cell viability assay in MCF7 cells transfected with CDK10
SMARTpool or siControl alone or in combination with p42/p44 MAPK SMARTpool siRNAs and treated with 4OH tamoxifen. Error bars represent the SEM. Right
panel: Western blot analysis of lysates prepared from MCF7 cells transfected with siRNA. An antibody recognizing p42/p44 MAPK was used with b-tubulin as
a loading control. The p42/p44 MAPK SMARTpools significantly reduced p42/p44 MAPK protein expression compared to siControl-transfected cells.
(D) Silencing of MEK1,2 restores 4OH tamoxifen sensitivity to CDK10-silenced cells. Left panel: Cell viability assay in MCF7 cells transfected with CDK10 SMART-
pool or siControl alone or in combination with MEK1,2 SMARTpool siRNAs and treated with 4OH tamoxifen. Error bars represent the SEM. Right panel: Western
blot analysis of lysates prepared from MCF7 cells transfected with siRNA. An antibody recognizing MEK1,2 was used with b-tubulin as a loading control. The
MEK1,2 SMARTpools significantly reduced MEK1,2 protein expression compared to siControl-transfected cells.is associated with clinical resistance to tamoxifen. As with the
previous data set, low CDK10 expression was not associated
with well-established prognostic factors, including age, tumor
size, grade, or node positivity (Table S4). In addition, low
98 Cancer Cell 13, 91–104, February 2008 ª2008 Elsevier Inc.CDK10 expression was not associated with the expression of
the biomarkers HER2, MIB1, p53, ERa, or PR (Figures S6A–S6F).
Promoter methylation is a common mechanism of transcrip-
tional repression. The methylation status of the CpG island in
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CDK10 Mediates Endocrine Therapy ResistanceFigure 6. Activation of the p42/p44 MAPK Pathway in CDK10 siRNA-Transfected Cells Occurs from Overexpression of c-RAF
(A) Increased levels of phosphorylated and total c-RAF in CDK10-silenced cells. MCF7 cells transfected 48 hr earlier with siRNA were treated with 1 nM estradiol
or 1 nM estradiol plus 100 nM 4OH tamoxifen, or left untreated. Lysates were made 24 hr following treatment. Antibodies recognizing phospho and total c-RAF
were used with b-tubulin as a loading control.
(B) Significantly higher expression of c-RAF in CDK10-silenced cells. qPCR on cDNA prepared from MCF7 cells transfected with siRNA for 48 hr followed by
treatment with 1 nM estradiol or 1 nM estradiol plus 100 nM 4OH tamoxifen, or left untreated for 24 hr. For CDK10 SMARTpool-transfected cells, p < 0.05 com-
pared to matched siControl-transfected cells (Student’s t test). Error bars represent the SEM.
(C) Silencing of c-RAF restores 4OH tamoxifen sensitivity to CDK10-silenced cells. Cell viability assay in MCF7 cells transfected with CDK10 SMARTpool or
siControl alone or in combination with c-RAF siRNA and treated with 4OH tamoxifen. *p < 0.05 compared to matched CDK10 siRNA sample (Student’s
t test). Error bars represent the SEM.
(D) CDK10-silenced cells do not have significantly higher levels of activated Ras. Ras activation assay on lysates prepared from MCF7-transfected with siRNA for 72 hr.
(E) Overexpression of wild-type c-RAF increases the levels of phosphorylated c-RAF. MCF7 cells were transfected with pEF wild-type c-RAF or pEF empty vector control,
and lysates were made 24 hr later. Antibodies recognizing phospho and total c-RAF were used with b-tubulin as a loading control.
(F) Overexpression of wild-type c-RAF increases the levels of phosphorylated p42/p44 MAPK. MCF7 cells were transfected with pEF wild-type c-RAF or pEF empty vector
control, and lysates were made 24 hr later. Antibodies recognizing phospho and total p42/p44 MAPK were used with b-tubulin as a loading control.the CDK10 promoter was assessed in genomic DNA extracted
from biopsies taken from the second set of breast tumors, using
methylation-specific PCR (MSP). Seven of thirty-eight (18%)
cases had methylation of the CDK10 promoter, and CDK10
promoter methylation was strongly associated with low CDK10
expression (Figure 8E). Methylation of the CDK10 promoter
was also associated with a statistically significantly shorter
time to disease progression (p < 0.0001, Figure S7A) and signif-
icantly shorter overall survival (p < 0.0001, Figure S7B). This
suggests a mechanism by which tumors develop low CDK10
expression levels resulting in tamoxifen resistance.DISCUSSION
Resistance to endocrine therapies is one of the major limiting
factors in the successful treatment of breast cancer, and strate-
gies to enhance the utility of these agents would be of significant
clinical benefit. Intracellular signaling pathways and their effects
on sensitivity to endocrine therapies have been the subject
of considerable study for some time. While much of this
work has been highly informative, it has relied on the study of
proteins whose function is consistent with the existing under-
standing of intracellular signaling. As a complement to these
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CDK10 Mediates Endocrine Therapy ResistanceFigure 7. Increased c-RAF Expression in CDK10-Silenced Cells Is Regulated by ETS2 Transcription Factor
(A) Expression of c-RAF in CDK10-silenced cells can be partially restored to normal levels by silencing of ETS2. MCF7 cells were transfected with CDK10 SMART-
pool alone or in combination with ETS2 SMARTpool siRNA or siControl and 48 hr later treated with 1 nM estradiol or 1 nM estradiol plus 100 nM 4OH tamoxifen, or
left untreated. RNA was made 24 hr following treatment and used for qPCR. The levels of c-RAF mRNA were significantly decreased when ETS2 was silenced in
combination with CDK10. For siControl- and CDK10 + ETS2 SMARTpool-transfected cells, p < 0.05 compared to matched CDK10 SMARTpool-transfected cells
(Student’s t test). Error bars represent the SEM.
(B) Levels of phosphorylated p42/p44 MAPK and c-RAF protein can be partially restored to normal levels by silencing of ETS2. MCF7 cells transfected 48 hr earlier
with siRNA were treated with 1 nM estradiol or 1 nM estradiol plus 100 nM 4OH tamoxifen, or left untreated. Lysates were made 24 hr following treatment.
Antibodies recognizing phospho and total p42/p44 MAPK and total c-RAF were used with b-tubulin as a loading control.
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CDK10 Mediates Endocrine Therapy ResistanceFigure 8. Low CDK10 Expression Is Associ-
ated with Significantly Poorer Survival in
Patients Treated with Tamoxifen
(A) Kaplan-Meier survival curves of breast cancer
patients from data set 1, n = 87, with tumors that
have low CDK10 expression (defined as lowest
quartile expression) were at significantly higher
risk of distant relapse, hazard ratio 2.447,
p = 0.0205 (log-rank test) when treated with adju-
vant tamoxifen. CDK10 expression was analyzed
using microarray analysis from a published study
(Loi et al., 2007).
(B) Kaplan-Meier survival curves of breast cancer
patients from data set 1, n = 87, with tumors that
have low CDK10 expression had a trend of
reduced overall survival, hazard ratio 1.992,
p = 0.0793 (log-rank test) when treated with adju-
vant tamoxifen. This is not statistically significant
but shows a trend to significance. CDK10 expres-
sion was analyzed using microarray analysis from
a published study (Loi et al., 2007).
(C) Kaplan-Meier survival curves of breast cancer
patients from data set 2, n = 38, with tumors that
have low CDK10 expression (defined as lowest
quartile expression) were at significantly higher
risk of distant relapse (hazard ratio not definable),
p < 0.0001 (log-rank test) when treated with adju-
vant tamoxifen. CDK10 expression was measured
using quantitative PCR.
(D) Kaplan-Meier survival curves of breast cancer
patients from data set 2, n = 38, with tumors that
have low CDK10 expression have significantly
reduced overall survival, hazard ratio 13.56,
p < 0.0001 (log-rank test) when treated with adju-
vant tamoxifen. CDK10 expression was measured
using quantitative PCR.
(E) Methylation status of the CDK10 promoter
in data set 2 was significantly associated with
expression of CDK10. Median CDK10 expression
in methylated samples = 0.13, median CDK10
expression in unmethylated samples = 1.32,
p < 0.0001 (Mann Whitney test).candidate-based approaches, we identified determinants of re-
sponse to tamoxifen using an unbiased loss-of-function screen.
The identification of CDK10 demonstrated the utility of this
approach, as this protein had not previously been implicated in re-
sistance to endocrine agents. Furthermore, delineation of the
mechanism by which CDK10 is likely to determine tamoxifen sen-
sitivity, via ETS2 transactivation of the c-RAF gene, suggests
a role for thisprotein in regulatingactivation of the MAPKpathway.
Finally, the correlations between CDK10 expression, methylation,and clinical outcome suggest that such unbiased approaches can
identify determinants that have clear clinical significance.
Integrating Complementary Functional Genomic
and Clinical Approaches
One approach to the identification of determinants of endocrine
therapy has been to use gene expression profiling, both on an
individual gene and a genome-wide basis (Jansen et al., 2005).
This approach, especially when carried out in a high-throughput(C) Silencing of ETS2 restores 4OH tamoxifen sensitivity to CDK10-silenced cells. Cell viability assay in MCF7 cells transfected with CDK10 SMARTpool or
siControl alone or in combination with ETS2 SMARTpool siRNA and treated with 4OH tamoxifen. * p < 0.05 compared to CDK10 siRNA (Student’s t test). Error
bars represent the SEM.
(D) CDK10 binds to ETS2. MCF7 cells were transfected with pReceiver CDK10 HA or the empty vector control pReceiver empty HA. Lysates were made 24 hr
later, and CDK10 was immunoprecipitated with HA-conjugated beads. ETS2 binding was detected by western blotting of the immunoprecipitated lysate.
(E) Diagram illustrating an ETS2 consensus-binding sequence identified in the c-RAF promoter using TFMATRIX (Score 96.0).
(F) CDK10 and ETS2 bind to the c-RAF promoter at the ETS2-binding site. MCF7 cells were transfected with pReceiver CDK10 HA or empty vector control
pReceiver HA for 24 hr and subsequently subjected to ChIP with the indicated antibodies. Shown are agarose gels with PCR products for the ETS2-binding
site on the c-RAF promoter and PCR products for a control region.
(G) ETS2 binding to the c-RAF promoter at the ETS2-binding site is increased in CDK10-silenced cells. MCF7 cells were transfected with CDK10 SMARTpool
siRNA or siControl for 48 hr and subsequently subjected to ChIP with the indicated antibodies. Shown are agarose gels with PCR products for the ETS2-binding
site on the c-RAF promoter and PCR products for a control region.
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correlations between transcript levels and clinical outcome.
However, the interpretation of such analysis is limited by the
inability to distinguish expression changes that are causative
to the clinical phenotype from those that are merely consequen-
tial. The combination of functional analysis such as RNAi screen-
ing followed by gene expression analysis in clinical samples
provides a powerful unbiased approach to the identification
of the key genetic causes of phenotypes such as drug resis-
tance.
CDK10 Regulates Expression of c-RAF
By integrating our data with previously published work, we
suggest a model by which CDK10 modulates intracellular signal-
ing and determines the response to tamoxifen and other endo-
crine therapies. We propose that CDK10 normally binds and
represses the ETS2 transcription factor, in agreement with pre-
viously published work (Kasten and Giordano, 2001). We identi-
fied an ETS2-binding site in the c-RAF promoter and using ChIP
demonstrated that both CDK10 and ETS2 bind to this site. In the
absence of CDK10 activity, c-RAF transcription is significantly
upregulated due to relief of ETS2 repression. This increase in
c-RAF expression leads to activation of downstream compo-
nents of the MAPK pathway, including MEK1,2 and p42/p44
MAPK, which increase the expression of CYCLIN D1 (Lavoie
et al., 1996), resulting in tamoxifen resistance by circumventing
the reliance upon estrogen signaling (Wilcken et al., 1997).
Clinical Significance of CDK10
Having identified CDK10 as a modifier of tamoxifen sensitivity,
we examined CDK10 expression in tamoxifen-treated breast
tumors to validate its clinical significance. Patients with low-
CDK10-expressing tumors were resistant to tamoxifen, consis-
tent with the functional effect of silencing CDK10 expression
identified in our RNAi screen. Furthermore, we identified methyl-
ation of theCDK10 promoter in a significant proportion of tumors
(18%), suggesting a mechanism for suppression of CDK10
expression. The significant association of clinical outcome with
methylation of the CDK10 promoter provides further evidence
that suppression of CDK10 is a key driver of resistance to tamox-
ifen. Given that the mechanism of tamoxifen resistance identified
in tumors with low CDK10 suggests loss of reliance on estrogen
signaling, low CDK10 expression may also be associated with
clinical resistance to other endocrine therapies such as aroma-
tase inhibitors. Our study identifies a subgroup of low-CDK10-
expressing, ERa-positive breast cancer patients that respond
poorly to endocrine therapies, and these patients may benefit
from alternative therapeutic approaches, including the use of
signal transduction inhibitors (Dancey and Sausville, 2003).
It is notable that previous studies have demonstrated an asso-
ciation between both p42/p44 MAPK activation and increased
CYCLIN D1 expression and tamoxifen resistance (Gee et al.,
2001; Kenny et al., 1999). Our data identify a possible mecha-
nism explaining these associations. In addition, elevated ETS2
expression and phosphorylation have been associated with
reduced disease-free survival in tamoxifen-treated patients
(Myers et al., 2005; Svensson et al., 2005), supporting the
hypothesis that increased ETS2 activity can cause resistance
to tamoxifen.
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This study reports a functional RNAi screen to systematically
identify the causes of tamoxifen resistance. We identified CDK10
as a modifier of tamoxifen sensitivity and established its mecha-
nism of action, regulation of the p42/p44 MAPK pathway. Impor-
tantly, we demonstrate the clinical significance of these findings.
Our work illustrates the power of combining systematic
functional approaches with gene expression profiling of tumor
samples.
EXPERIMENTAL PROCEDURES
Detailed Experimental Procedures are available in the Supplemental Data.
Cell Lines, Compounds, Antibodies, Plasmids, and siRNA
MCF7 cells were obtained from ATCC (USA) and maintained in phenol-
red-free RPMI 1640 (Invitrogen), supplemented with 10% dextran charcoal-
treated FCS (10% (v/v)), 1 nM estradiol, glutamine, and antibiotics. 4OH
tamoxifen and estradiol were obtained from Sigma. ICI 182780 was obtained
from Tocris Bioscience UK. The pReceiver CDK10 HA plasmid (EX-Q0187-
M08) was obtained from Genecopoeia (USA). The pEF wild-type c-RAF plas-
mid was a kind gift from Professor Richard Marais (ICR, UK). MCF7 cells were
transfected with SMARTpool siRNAs using Dharmafect 3 transfection reagent
according to the manufacturer’s instructions (Dharmacon). The protein kinase
siRNA library (siARRAY, targeting 779 known and putative human protein
kinase genes) was obtained in ten 96-well plates from Dharmacon (USA).
Each well in this library contained a SMARTpool of four distinct siRNA species
targeting different sequences of the target transcript. Details of antibodies
used are provided in the Supplemental Experimental Procedures.
HTS Method
MCF7 cells (2500 per well) were plated in 96-well plates and transfected 24 hr
later with siRNA (final concentration 100 nM), using Dharmafect 3 (Dharmacon,
USA). Twenty-four hours after transfection, cells were trypsinized and divided
into four identical replica plates. At 48 hr following transfection, two replica
plates were treated with 50 nM 4OH tamoxifen in media and two replica plates
with 0.05% ethanol vehicle in media. Media containing 4OH tamoxifen or
vehicle were replenished after 48 hr and 96 hr, and cell viability was assessed
after 7 days 4OH tamoxifen exposure using CellTiter Glo Luminescent Cell
Viability Assay (Promega, USA) as per the manufacturer’s instructions. The
luminescence reading for each well on a plate was expressed relative to the
median luminescence value of all wells on the plate. The screen was com-
pleted in duplicate. For each transfection the effects on cell growth and tamox-
ifen sensitivity were calculated. Details of the calculations are described in the
Supplemental Experimental Procedures.
Validation of HTS
Four distinct siRNA species targeting each gene were used to revalidate hits
from the screen. A significance threshold of p < 0.05 (Student’s t test) was
used for each individual siRNA. Validation of RNAi gene silencing was mea-
sured by quantitative PCR as described in the Supplemental Experimental
Procedures.
Cell Viability Assays to Measure Drug Sensitivity
MCF7 cells were transfected with siRNA using Dharmafect 3, divided 24 hr
later into 96-well plates, and exposed to various doses of drug from 48 hr post-
transfection. Cell viability was assessed by CellTiter Glo Luminescent Cell
Viability Assay (Promega, USA) at 9 days posttransfection, and the surviving
fraction for each dose of drug was calculated by dividing the luminescence
value from drug-treated wells by the luminescence value in vehicle-treated
wells.
Quantitative PCR
MCF7 cells were transfected with siRNA using Dharmafect 3, and after 24 hr
the media were refreshed with no estradiol, 1 nM estradiol, or 1 nM estradiol
with 100 nM 4OH tamoxifen. RNA was extracted 48 hr later and cDNA
Cancer Cell
CDK10 Mediates Endocrine Therapy Resistancesynthesized using SuperScript III First Strand Synthesis System for RT-PCR
(Invitrogen) with oligo dT. Real-time qPCR was performed using Assay-on-
Demand primer/probe sets from Applied Biosystems (Foster City, CA), with
endogenous control GAPDH. Gene expression was calculated relative to
expression of GAPDH endogenous control and adjusted relative to expression
in siControl-transfected cells.
Fluorescence-Activated Cell Scanning Analysis
MCF7 cells were transfected with siRNA using Dharmafect 3, and after 24 hr the
media were refreshed with no estradiol, 1 nM estradiol, or 1 nM estradiol with
100 nM 4OH tamoxifen. After 48 hr the cells were fixed in 70% ice-cold ethanol
and stained with 4% propidium iodide (PI) and 10% RNase A in PBS. The sam-
ple readout was performed on the FACSCalibur (Becton Dickinson, USA), and
the data were analyzed using CellQuest Pro (Becton Dickinson, USA).
Caspase 3/7 Activation Assay
MCF7 cells were transfected with siRNA using Dharmafect 3. Twenty-four
hours after transfection, media were refreshed with various concentrations
of 4OH tamoxifen. Forty-eight hours after transfection, caspase 3/7 activation
was assessed using Caspase-Glo 3/7 Assay (Promega), as per the manufac-
turer’s instructions.
Ras Activation Assay
MCF7 cells were transfected with siRNA using Dharmafect 3, and after 24 hr
the media were refreshed with RPMI 1640 without phenol red. After 48 hr
the cells were lysed. The activation of Ras was assessed by the use of
a Ras Activation Assay Kit (Cell Biolabs, CA). In brief, activated GTP-Ras
was isolated from cell lysates by the use of agarose beads conjugated to
the Ras-binding domain of c-RAF. The amount of GTP-Ras was quantified
by the western blotting of purified samples with a mouse monoclonal antibody
recognizing all three isoforms of Ras.
Co-IP
MCF7 cells were transfected with pReceiver CDK10 HA or the empty vector
control pReceiver empty HA, using Fugene 6 as per the manufacturer’s
instructions. After 24 hr the cells were lysed in lysis buffer and total cell lysates
were used for Co-IP.
Identification of ETS2-Binding Site
The ETS2-binding site in the c-RAF promoter was identified using the
TFMATRIX transcription factor-binding site database (Wingender et al., 1996).
ChIP Assay
MCF7 cells were transfected with pReceiver CDK10 HA or the empty vector
control pReceiver empty HA using Fugene 6, or CDK10 SMARTpool siRNA
or siControl using Dharmafect 3. After 24 hr, or 48 hr, respectively, the cells
were lysed and the ChIP assay was performed using the ChIP Assay Kit ac-
cording to the manufacturer’s instructions (17-295, Upstate, UK). Antibodies
used for immunoprecipitation were HA (sc-805, Santa Cruz, USA), ETS2
(ab37214, abcam, USA), and normal rabbit IgG (sc-2027, Santa Cruz, USA).
PCR primers were designed to flank the putative ETS2-binding site of the
c-RAF promoter at position 545. Control PCR primers flanked an amplicon
of similar size in EGFR exon 21. Primer sequences are available upon request.
Patients and Clinical Tissue Samples for MSP and qPCR
Primary breast cancer samples were obtained as paraffin-embedded tissue
sections. Tissues were obtained with fully informed consent and Ospedale
Santa Croce e Carle Local Ethics Committee approval.
Bisulfite Modification and MSP
Genomic DNA was subjected to modification with sodium bisulphite as
described previously (Smith et al., 2007). Methylation-specific PCR was per-
formed with multiple primer pairs encompassing different regions of the
CpG island located at the 50 end of the CDK10 gene. Primer sequences are
available upon request.Supplemental Data
The Supplemental Data include Supplemental Experimental Procedures,
seven supplemental figures, and four supplemental tables and can be found
with this article online at http://www.cancercell.org/cgi/content/full/13/2/91/
DC1/.
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